Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025
Hoth Therapeutics (NASDAQ: HOTH) announced that CEO Robb Knie will present at BIO-Europe 2025 in Vienna, Austria, on November 3–5, 2025. The presentation will highlight progress on two clinical programs: HT-001, a topical treatment for rash and skin toxicity from cancer therapies including EGFR inhibitors and radiotherapy, and HT-KIT, a precision oncology program targeting KIT-driven tumors.
The company said it will discuss clinical pipeline updates and engage with potential collaborators. Presentation timing and partnering meetings will be available to registered attendees via the BIO-Europe partneringONE platform.
Hoth Therapeutics (NASDAQ: HOTH) ha annunciato che il CEO Robb Knie parlerà a BIO-Europe 2025 a Vienna, in Austria, dal 3 al 5 novembre 2025. La presentazione evidenzierà i progressi su due programmi clinici: HT-001, un trattamento topico per eritemi e tossicità cutanea derivanti da terapie antitumorali tra cui inibitori EGFR e radioterapia, e HT-KIT, un programma di oncologia di precisione mirato a tumori guidati da KIT.
L'azienda ha dichiarato che discuterà aggiornamenti sul portafoglio clinico e si confronterà con potenziali partner. Il tempo di presentazione e le riunioni di partenariato saranno disponibili per i partecipanti registrati tramite la piattaforma BIO-Europe partneringONE.
Hoth Therapeutics (NASDAQ: HOTH) anunció que su CEO Robb Knie presentará en BIO-Europe 2025 en Viena, Austria, del 3 al 5 de noviembre de 2025. La presentación destacará el progreso de dos programas clínicos: HT-001, un tratamiento tópico para erupciones y toxicidad cutánea derivadas de terapias contra el cáncer, incluyendo inhibidores de EGFR y radioterapia, y HT-KIT, un programa de oncología de precisión orientado a tumores impulsados por KIT.
La empresa dijo que discutirá actualizaciones del portafolio clínico y trabajará con posibles colaboradores. El horario de presentación y las reuniones de asociaciones estarán disponibles para los asistentes registrados a través de la plataforma BIO-Europe partneringONE.
Hoth Therapeutics (NASDAQ: HOTH)은/는 CEO Robb Knie가 오스트리아 비엔나에서 열리는 BIO-Europe 2025에서 2025년 11월 3–5일에 발표할 것이라고 발표했습니다. 발표는 두 가지 임상 프로그램의 진행 상황을 강조할 예정입니다: HT-001, EGFR 억제제 및 방사선 치료를 포함한 암 치료에 따른 발진과 피부 독성에 대한 국소 치료제, 그리고 HT-KIT, KIT 구동 종양을 겨냥하는 정밀 종양학 프로그램입니다.
회사는 임상 파이프라인 업데이트를 논의하고 잠재적 협력자와 소통할 것이라고 밝혔습니다. 발표 시간 및 파트너십 미팅은 BIO-Europe partneringONE 플랫폼을 통해 등록된 참석자에게 제공됩니다.
Hoth Therapeutics (NASDAQ: HOTH) a annoncé que le PDG Robb Knie présentera lors du BIO-Europe 2025 à Vienne, en Autriche, du 3 au 5 novembre 2025. La présentation mettra en avant les progres de deux programmes cliniques : HT-001, un traitement topique pour l'éruption et la toxicité cutanée associées aux thérapies anticancéreuses, y compris les inhibiteurs d'EGFR et la radiothérapie, et HT-KIT, un programme d'oncologie de précision ciblant les tumeurs guidées par KIT.
L'entreprise a indiqué qu'elle discuterait des mises à jour du pipeline clinique et s'entretiendra avec d'éventuels partenaires. Le planning de la présentation et les réunions de partenariat seront disponibles pour les participants inscrits via la plateforme BIO-Europe partneringONE.
Hoth Therapeutics (NASDAQ: HOTH) gab bekannt, dass CEO Robb Knie auf der BIO-Europe 2025 in Wien, österreich, vom 3. bis 5. November 2025 präsentieren wird. Die Präsentation wird Fortschritte in zwei klinischen Programmen hervorheben: HT-001, eine topische Behandlung für Hautausschälte und Hauttoxizität durch Krebstherapien einschließlich EGFR-Hemmern und Strahlentherapie, und HT-KIT, ein Programm der Präzisionsonkologie, das KIT-gesteuerte Tumore anspricht.
Das Unternehmen sagte, es werde Aktualisierungen der klinischen Pipeline diskutieren und sich mit potenziellen Kooperationspartnern austauschen. Die Präsentationszeiten und Partnering-Meetings werden registrierten Teilnehmerinnen und Teilnehmern über die BIO-Europe partneringONE-Plattform zugänglich sein.
Hoth Therapeutics (NASDAQ: HOTH) أعلنت أن الرئيس التنفيذي روبي كني سيقدم في BIO-Europe 2025 في فيينا، النمسا، في الفترة من 3–5 نوفمبر 2025. ستسلط العرض الضوء على التقدم في برنامجين سريريين: HT-001، علاج موضعي للطفح الجلدي وسمّية الجلد الناتجة عن علاجات السرطان بما فيها مثبطات EGFR والعلاج الإشعاعي، وHT-KIT، برنامج الأورام الدقيقة الذي يستهدف الأورام القيادية بـ KIT.
قالت الشركة إنها ستناقش تحديثات خط الأنابيب السريري وتتفاعل مع شركاء محتملين. ستكون أوقات العرض واجتماعات الشراكة متاحة للحاضرين المسجلين عبر منصة BIO-Europe partneringONE.
Hoth Therapeutics (NASDAQ: HOTH) 宣布，首席执行官 Robb Knie 将在 BIO-Europe 2025 于奥地利维也纳举行时发表讲话，时间为 2025年11月3–5日。此次演讲将重点介绍两个临床计划的进展：HT-001，一种用于癌症治疗包括EGFR抑制剂和放疗所引发的皮疹及皮肤毒性的外用治疗，以及 HT-KIT，一个瞄准 KIT 驱动肿瘤的精准肿瘤学计划。
公司表示将讨论临床管线更新，并与潜在合作者进行接触。演讲时间安排和对外洽谈会议将通过 BIO-Europe partneringONE 平台向注册参会者开放。
- None.
- None.
Presentation to highlight advancements in Hoth's clinical pipeline, including
HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program
targeting KIT-driven tumors
At the conference, Mr. Knie will highlight the Company's two leading development programs:
- HT-001 – a topical therapeutic designed to reduce rash and skin toxicity associated with cancer therapies, including EGFR inhibitors and radiotherapy.
- HT-KIT – a precision oncology program targeting cancers driven by dysregulated KIT signaling.
"BIO-Europe is one of the premier global events for biopharma partnering and innovation," said Robb Knie, CEO of Hoth Therapeutics. "We look forward to sharing progress on our lead programs and engaging with potential collaborators who share our vision of developing breakthrough therapies for patients with high unmet needs."
Hoth's presentation and partnering schedule will be available to registered attendees through the BIO-Europe® partneringONE platform.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-ceo-robb-knie-to-present-at-bio-europe-in-vienna-austria-november-35-2025-302576610.html
SOURCE Hoth Therapeutics, Inc.
FAQ
When will Hoth Therapeutics (HOTH) present at BIO-Europe 2025?
What programs will Hoth (HOTH) discuss at the November 2025 BIO-Europe presentation?
How can investors or partners view Hoth's (HOTH) BIO-Europe presentation and schedule?
Does Hoth (HOTH) plan to seek collaborators at BIO-Europe 2025?
Will Hoth (HOTH) present clinical data for HT-001 or HT-KIT at BIO-Europe 2025?
